FY2019 · ended Dec 31, 2019 · Revenue $143,322, +405.6% YoY · Filed Mar 30, 2020
Sigyn Therapeutics, Inc. (SIGY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. As of Sep 30, 2025 it held $85,571 in cash and investments and $4.0 million in total debt.
Revenue (TTM)
$9,929
-92.8% vs year-ago TTM
Net income (TTM)
$-3.68M
-159.4% vs year-ago TTM
Operating cash flow (TTM)
$-936,426
-31.9% vs year-ago TTM
Free cash flow
$-1.83M
-1.5% vs prior year
EPS (TTM)
$-0.05
+38.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
1.61M
+31.1% vs prior year
Net cash
$-3.90M
as of Sep 30, 2025
Operating margin
-7019.1%
FY 2020
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SIGY (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Beverly Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642159
- Former names
- Reign Resources Corp (until Oct 23, 2020); Reign Sapphire Corp (until May 12, 2020)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Operating income | -$2.5M | -$2.5M | -$2.1M | -$2.0M | -$916,434 |
| Net income | -$3.3M | -$4.1M | -$2.9M | -$3.0M | -$1.3M |
| Diluted EPS | -$2.51 | -$3.77 | — | — | — |
| Operating cash flow | -$872,436 | -$1.4M | -$1.8M | -$1.8M | -$829,809 |
| Free cash flow | — | — | -$1.8M | -$1.8M | — |
| Total assets | $213,719 | $321,806 | $332,879 | $710,259 | $694,082 |
| Total liabilities | $4.7M | $3.7M | $2.2M | $974,843 | $594,903 |
| Stockholders' equity | -$4.5M | -$3.4M | -$1.9M | -$264,584 | $99,179 |
| Cash and investments | $12,144 | $11,690 | $8,356 | $340,956 | $84,402 |
| Total debt | $2.3M | $2.7M | $2.5M | $286,716 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Feb 20, 2026 | Feb 20, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
| 10-Q | Quarterly report | Sep 5, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change, Other events
|
Aug 15, 2025 | Aug 14, 2025 |
| 10-Q | Quarterly report | May 20, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Apr 15, 2025 | Dec 31, 2024 |
All 175 Sigyn Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.